Role of NGAL in Acute Kidney injury with Liver cirrhosis

Not yet recruiting

Brief Summary: Acute kidney injury (AKI) is a common complication occurring in cirrhotic patients. The morbidity and mortality rate of patients with cirrhosis of the liver with AKI is increasing at an alarming rate. Current practical biomarker serum creatinine has several limitations and cannot differentiate acute kidney injury AKI. Differentiation of AKI is vital for a good prognosis and helps in therapy. Several promising biomarkers have been identified during the last 10 years and among them, urine Neutrophil gelatinase-associated lipocalin (NGAL) appears to be a promising marker for diagnosis of AKI. Recent studies showed that NGAL excels as an early biomarker and helps in the differential diagnosis.

Based on this background knowledge, a study will be prospectively carried out for three years on Liver cirrhosis patients diagnosed with AKI visiting or admitted under the Nephrology and Department of Gastroenterology and hepatology. Patients recruited for the study will be diagnosed with AKI based on the ICA (The international club of ascites) criteria and evaluated to discover its etiology. The urine sample will be collected at the time of admission to evaluate the role of the most promising biomarkers Neutrophil gelatinase-associated lipocalin (NGAL) in the differential diagnosis of AKI and to see its association with the progression of AKI and the mortality

Recruitment & Eligibility

Inclusion Criteria

Clinically diagnosed with cirrhosis of the liver with AKI as per ICA criteria.

Exclusion Criteria

Kidney or liver transplant Chronic hemodialysis before admission or receiving nephrotoxic medications.
Chronic kidney disease Renal insufficiency or urinary obstruction Hepatocellular carcinoma or any other advanced malignancy UTI (Urinary tract infection) (Positive urine culture or urine WBC > 10 per high power field) Septic shock Lack of informed consent.

Primary Outcome Measures

Name	Time	Method
To study the impact of type and severity of AKI on mortality and hospital stay	2 years
To study the clinical profile, risk factors for AKI in Liver cirrhosis patients.	2 years

Secondary Outcome Measures

Name	Time	Method
To determine the ability of uNGAL to differentiate different types of AKI.	To determine the optimal cut-off value of uNGAL in different types of AKI using ROC

Locations (1): Kasturba Medical College
🇮🇳
Udupi, KARNATAKA, India
Kasturba Medical College
🇮🇳Udupi, KARNATAKA, India
Dr Shiran shetty
Principal investigator
8861920517
shiran.shetty@manipal.edu